. 2012 Feb;50(2):227–231. doi: 10.1128/JCM.06036-11

Table 3.

Detailed characteristics of the 353 BAL fluids studied, presented according to IFA and qPCR results

Patient category^a	No. (%) of BAL fluid samples	No. of patients (%)	IFA-positive/qPCR-positive samples				IFA-negative/qPCR-positive samples				IFA-negative/qPCR-negative samples
			Total (%)	Mean log copy no. (SD)	No. from patients with:		Total (%)	Mean log copy no. (SD)	No. from patients with:		Total (%)	No. from patients with:
			Total (%)	Mean log copy no. (SD)	Lesions^b	PcP prophylaxis	Total (%)	Mean log copy no. (SD)	Lesions^b	PcP prophylaxis	Total (%)	Lesions^b	PcP prophylaxis
Total	353	287	17		15	1	63		27	2	273	94	51
HIV⁺ patients	46 (13)	39 (14)	8 (47)	5.5 (0.9)	8 (53)	0	4 (6)	2.1 (1.2)	3 (11)	0	34 (12)	15 (16)	19 (37)
≥200 CD4⁺ T cells/μl	16/46	13/39	0/8			0	1/4		0	0	15/34	8/15	4/19
<200 CD4⁺ T cells/μl	30/46	26/39	8/8		8/8	0	3/4		3/3	0	19/34	7/15	15/19
Hematology patients	147 (42)	111 (39)	6 (35)	4.2 (0.8)	4 (27)	0	24 (38)	1.3 (0.9)	8 (30)	2 (100)	117 (43)	36 (38)	22 (43)
Acute leukemia	73/147	49/111	3/6		3/4	0	15/24		4/8	0	55/117	18/36	9/22
CLD	74/147	62/111	3/6		1/4	0	9/24		4/8	2/2	62/117	18/36	13/22
SOT recipients	57 (16)	47 (16)	2 (12)	4.6 (0.7)	2 (13)	1	10 (15.9)	1.4 (1.0)	3 (11)	0	45 (16)	17 (18)	6 (12)
Heart	11/57	11/47	0/2		0	0	4/10		0	0	7/45	2/17	2/6
Liver	17/57	13/47	2/2		2	1	1/10		1/3	0	14/45	5/17	2/6
Kidney	29/57	23/47	0/2		0	0	5/10		2/3	0	24/45	10/17	2/6
Patients with SID	53 (15)	47 (16)	1 (6)	3.5	1 (7)	0	16 (25.4)	0.7 (1.0)	6 (22)	0	36	10 (11)	3 (6)
Patients with solid tumors	18 (5)	16 (6)	0	0	0	0	7 (11.1)	1.3 (1.4)	6 (22)	0	11	4 (4)	1 (2)
Others	32 (9)	27 (9)	0	0	0	0	2 (3)	0.2 (0.1)	1 (4)	0	30	12 (13)	0

CLD, chronic lymphoproliferative disorders; SOT, solid-organ transplant; SID, systemic inflammatory diseases.

Diffuse radiological lesions.